Table 1 Clinical characteristics of all patients.
From: Genomic landscape of extraordinary responses in metastatic breast cancer
Pt | ER/HER2 | Age | Initial stage | Site of metastases | Treatment | PFS (mo.) |
|---|---|---|---|---|---|---|
1 | HER2+ | 57 | 4 | Lung | Herceptin + taxane followed by herceptin maintenance | 86.0+ |
2 | HER2+ | 41 | 4 | Brain | TDM1 | 62.9+ |
3 | HER2+ | 49 | 4 | Bone, lung | Herceptin + taxane followed by herceptin maintenance | 49.9+ |
4 | HER2+ | 39 | 3 | Ovary | Herceptin + taxane followed by herceptin maintenance | 37.9 |
5 | HER2+ | 67 | 1 | Liver | Xeloda + lapatinib | 34.5 |
6 | HER2+ | 62 | 4 | Axillary lymph node, bone | Herceptin + taxane followed by herceptin maintenance | 34.4 |
7 | ER+ | 74 | 2 | Pleura | Letrozole | 100.3+ |
8 | ER+ | 58 | 4 | Ipsilateral axillary lymph node, lung, liver, bone, brain | Anastrozole | 100+ |
9 | ER+ | 56 | 1 | Lung | Letrozole | 87+ |
10 | ER+ | 49 | 3 | Lung | Tamoxifen | 73+ |
11 | ER+ | 48 | 4 | Pleura | Tamoxifen | 72.8+ |
12 | ER+ | 46 | 2 | Bone | Letrozole/leuprorelin | 71+ |
13 | ER+ | 61 | 3 | Pleura, mediastinal LN | Letrozole | 69+ |
14 | ER+ | 44 | 2 | Bone | Everolimus/exemestane | 63+ |
15 | ER+ | 60 | 2 | Liver | Letrozole | 62.1+ |
16 | ER+ | 54 | 4 | Liver | Letrozole | 62+ |
17 | ER+ | 52 | 2 | Pleura, lung | Anastrozole | 61.6+ |
18 | ER+ | 551 | 2 | Pleura, mediastinum | Letrozole | 61.4+ |
19 | ER+ | 691 | 1 | Pleura | Everolimus/exemestane | 61+ |
20 | ER+ | 512 | 2 | Lung | Everolimus/letrozole/leuprorelin | 61+ |
21 | ER+ | 592 | 3 | Bone | Letrozole | 61+ |
22 | ER+ | 58 | 1 | Lung | Arimidex | 60.5+ |
23 | ER+ | 50 | 3 | Multiple bone | Everolimus/letrozole/leuprorelin | 59+ |
24 | ER+ | 52 | 3 | Liver | Everolimus/letrozole/leuprorelin | 49+ |
25 | ER+ | 48 | 2 | Liver, ovary | Femara | 47.1+ |
26 | ER+ | 69 | 4 | Pericardial, ipsilateral cervical LN | Letrozole | 42+ |
27 | ER+ | 72 | 4 | Stomach | Letrozole | 34+ |
28 | ER+ | 51 | 2 | Lung | Letrozole/leuprorelin | 28+ |
29 | ER+ | 56 | 3 | Bone | Everolimus/exemestane | 23+ |
30 | ER+ | 52 | 4 | Bone | Paclitaxel | 10.6+ |
Non-responders | ||||||
1 | HER2+ | 56 | 4 | Liver, lung | Herceptin + taxane | 7.2 |
2 | ER+ | 57 | 1 | Bone | Letrozole | 12.2 |
3 | ER+ | 59 | 4 | Bone | Letrozole, LY2835219 or placebo | 9.6 |
4 | ER+ | 40 | 4 | Lung | Letrozole | 8.1 |
5 | ER+ | 58 | 4 | Liver | Letrozole | 7.4 |
6 | ER+ | 49 | 4 | Bone, liver | Tamoxifen, Goserelin | 6.6 |
7 | ER+ | 56 | 4 | Bone, distant LN | Tamoxifen, Goserelin | 5.9 |
8 | ER+ | 55 | 4 | Lung | Letrozole | 5.5 |
9 | ER+ | 59 | 4 | Liver, axillary LN | Letrozole, palbociclib | 4.9 |
10 | ER+ | 49 | 4 | Brain, liver | Letrozole | 4.6 |
11 | ER+ | 43 | 1 | Lung | Letrozole | 4 |
12 | ER+ | 63 | 3 | Bone | Femara + ibrance | 2.3 |
13 | ER+ | 49 | 1 | Distant LN | Letrozole, palbociclib | 2.1 |
14 | ER+ | 36 | 2 | Bone | Tamoxifen | 1 |
15 | ER+ | 49 | 4 | Bone | Tamoxifen | 0.96 |
